- Perrigo files regulatory application for Taclonex generic
- Merck's hepatitis C drug granted priority review by FDA
- Sanofi successfully switches Allegra
- New alliance will crack down on adulterated products touting dietary supplement claims
- NACDS responds to report on integrity of pharmaceutical supply chain
ALLEGAN, Mich. — Following the warning letter it received last April, Perrigo announced that the Food and Drug Administration has arrived at the company's Allegan, Mich.-based facility for re-inspection.
The re-inspection of the plant follows an initial inspection that occurred between Nov. 17, 2009, and Jan. 14, 2010, in which the FDA "identified significant violations of current good manufacturing practice regulations for finished pharmaceuticals," the regulatory agency said in its letter last year, noting certain production problems, including an equipment failure that shredded metal shavings into bottles on a production line of 200-mg ibuprofen tablets.